Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Han Ying
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have provided written informed consent
Age 18-75 years;
BMI 17-28 kg/m2
Male or female with a diagnosis of PBC, by at least two of the following criteria:
1. History of AP above ULN for at least six months;
2. Positive AMA titers (\>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies;
3. Documented liver biopsy result consistent with PBC.
Not receiving UDCA treatment before enrollment, ALP\>ULN
You may not be if
History or presence of other concomitant liver diseases.
ALT or AST \> 5×ULN, TBIL \> 3×ULN.
If female: known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating.
Allergic to fenofibrate or ursodeoxycholic acid.
Taking hepatotoxic drugs (e.g., dapsone, erythromycin, fluconazole, ketoconazole, rifampicin) for more than 2 weeks within 6 months, and long-term hormonal users.
Recurrent variceal bleeding, poorly controlled hepatic encephalopathy or refractory ascites.
Patients with a history of severe cardiac, cerebrovascular, renal, respiratory disease or functional failure, and psychiatric disorders (including those due to alcohol and drug abuse).
Creatinine \>1.5×ULN and creatinine clearance \<60 ml/min.
Currently using statins (such as pravastatin, fluvastatin, and simvastatin), other fibrates (such as gemfibrozil and bezafibrate), and drugs structurally similar to fenofibrate (like ketoprofen).
Planned to receive an organ transplant or an organ transplant recipient.
Needing Liver transplantation within 1 year according to the Mayo Rick score.
Any other condition(s) that would compromise the safety of the subject or compromise